Chinese Expert Consensus on the Use of Biologics in Patients with Chronic Rhinosinusitis (2022, Zhuhai)
| العنوان: | Chinese Expert Consensus on the Use of Biologics in Patients with Chronic Rhinosinusitis (2022, Zhuhai) |
|---|---|
| المؤلفون: | Hai-yu Hong, Teng-yu Chen, Qin-tai Yang, Yue-qi Sun, Feng-hong Chen, Hong-fei Lou, Hong-tian Wang, Rui-li Yu, Yun-fang An, Feng Liu, Tian-sheng Wang, Mei-ping Lu, Qian-hui Qiu, Xiang-dong Wang, Jian-jun Chen, Cui-da Meng, Zhi-hai Xie, Juan Meng, Ming Zeng, Cheng-li Xu, Ying Wang, Yu-cheng Yang, Wei-tian Zhang, Jun Tang, Yan-li Yang, Rui Xu, Guo-dong Yu, Zhao-hui Shi, Xin Wei, Hui-ping Ye, Ya-nan Sun, Shao-qing Yu, Tian-hong Zhang, Jun Yong, Wei Hang, Yuan-teng Xu, Yu Xu, Guo-lin Tan, Na Sun, Gui Yang, You-jin Li, Jing Ye, Ke-jun Zuo, Li-qiang Zhang, Xue-yan Wang, An-ni Yang, Ying-xiang Xu, Wei Liao, Yun-ping Fan, Hua-bin Li |
| المصدر: | ORL. :1-13 |
| بيانات النشر: | S. Karger AG, 2023. |
| سنة النشر: | 2023 |
| مصطلحات موضوعية: | Otorhinolaryngology |
| الوصف: | Background: Chronic rhinosinusitis (CRS) is a common inflammatory disease in otolaryngology, mainly manifested as nasal congestion, nasal discharge, facial pain/pressure, and smell disorder. CRS with nasal polyps (CRSwNP), an important phenotype of CRS, has a high recurrence rate even after receiving corticosteroids and/or functional endoscopic sinus surgery. In recent years, clinicians have focused on the application of biological agents in CRSwNP. However, it has not reached a consensus on the timing and selection of biologics for the treatment of CRS so far. Summary: We reviewed the previous studies of biologics in CRS and summarized the indications, contraindications, efficacy assessment, prognosis, and adverse effects of biologics. Also, we evaluated the treatment response and adverse reactions of dupilumab, omalizumab, and mepolizumab in the management of CRS and made recommendations. Key Messages: Dupilumab, omalizumab, and mepolizumab have been approved for the treatment of CRSwNP by the US Food and Drug Administration. Type 2 and eosinophilic inflammation, need for systemic steroids or contraindication to systemic steroids, significantly impaired quality of life, anosmia, and comorbid asthma are required for the use of biologics. Based on current evidence, dupilumab has the prominent advantage in improving quality of life and reducing the risk of comorbid asthma in CRSwNP among the approved monoclonal antibodies. Most patients tolerate biological agents well in general with few major or severe adverse effects. Biologics have provided more options for severe uncontrolled CRSwNP patients or patients who refuse to have surgery. In the future, more novel biologics will be assessed in high-quality clinical trials and applied clinically. |
| تدمد: | 1423-0275 0301-1569 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::cef9031303b316d4e1c2970aef1bd5cf https://doi.org/10.1159/000529918 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi...........cef9031303b316d4e1c2970aef1bd5cf |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14230275 03011569 |
|---|